Indoleamine 2, 3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy

Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Lakshmi Bollu, April Bell, Miri Kim, Erik Rabin, Derek A. Wainwright

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Indoleamine 2, 3-dioxygenase 1 (IDO; IDO1) is expressed in > FoxP3+). Since IDO is canonically characterized as a rate-limiting enzyme that metabolizes the essential amino acid, tryptophan (Trp), into kynurenine (Kyn), the depletion of Trp and/or accumulation of Kyn has been the presumed mechanism of how IDO suppresses the anti-GBM immune response. However, our work has challenged this hypothesis, and here we provide a comprehensive update of IDO effects in adults with GBM.

Original languageEnglish (US)
Title of host publicationImmunotherapeutic Strategies for the Treatment of Glioma
PublisherElsevier
Pages127-151
Number of pages25
ISBN (Electronic)9780128197554
DOIs
StatePublished - Jan 1 2021

Keywords

  • Age
  • Glioblastoma
  • Glioma
  • IDO1
  • Immunosuppression
  • Immunotherapy
  • Kynurenine
  • Metabolism
  • Treg

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Indoleamine 2, 3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy'. Together they form a unique fingerprint.

Cite this